Gabapentin, also known as Neurontin, has long been a stable and effective treatment for patients who experience seizures, certain forms of epilepsy and pain from shingles. New research has indicated another effectual use for Gabapentin, CAS 60142-96-3, as a treatment to help combat symptoms of severe morning sickness. Known as hyperemesis gravidarum, this extreme form of morning sickness affects many pregnant women across the globe, including the Duchess of Cambridge, Kate Middleton. In this study, published in December 2012, women suffering from this debilitating condition were recruited. All of the women had tried previous options to combat their morning sickness, specifically anti-emetics. Often used to treat patients undergoing chemotherapy, anti-emetics are usually efficacious for controlling extreme nausea and vomiting. However, the women in this pilot study conducted at the UB School of Medicine and Biomedical Sciences in N.Y. found that these traditional anti-emetic treatments did not alleviate their symptoms of severe morning sickness. Dr. Thomas Guttuso, assistant professor of neurology in the UB School of Medicine and Biomedical Science initiated this open-label, pilot study to examine the safety, tolerability and effectiveness of Gabapentin in treating women with hyperemesis gravidarum.
“within only 2 hours of administration most of the patients felt well enough to eat and drink again, and hold the food down”
Results from this small, but revealing study showed a dramatic improvement in women once they started taking Gabapentin. In fact, within only 2 hours of administration most of the patients felt well enough to eat and drink again, and hold the food down. This pilot study also demonstrated that after two weeks of therapy with Gabapentin 80 percent of the women noted a substantial reduction in their nausea and as well as a 94 percent reduction in their vomiting. The FDA has approved further studies of Gabapentin for the treatment of hyperemesis gravidarum in pregnant women, and Dr. Guttuso has recently applied for a grant from the National Institutes of Health to further this clinical research. LGM Pharma provides API and Teva API Gabapentin for research and development purposes, and offers clients continued support throughout the R&D process.
The patent for Neurontin (Gabapentin) is set to expire for Pfizer on April 25, 2017, which will open up pathways for generic forms of this crucial and viable medication. Gabapentin is normally used to treat adults and children with epilepsy and seizures. Gabapentin works by affecting the chemicals and nerves in the body that can cause seizures. Adults with nerve pain that is caused by shingles are also often prescribed Gabapentin for pain relief. Side effects are typically mild, and may include headache, dry mouth, dizziness and drowsiness.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.